EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling

Liuyifei Huang, Jingli Gao, Yan Xing, Xiaoxuan Ning, Lei Wei, Peng He, Yifan Yang, Xiao Bai, Limin Liu, Shiren Sun

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2025.115902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Liuyifei Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Xijing Hospital, Air force Medical University, Xi'an, Shaanxi, China; Department of Nephrology, Xijing Hospital, Air force …. Hauptthemen laut MEDLINE: Twist-Related Protein 1, Harmine, Renal Insufficiency, Chronic, Nuclear Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis, a pathological hallmark of chronic kidney disease (CKD), accounts for over 40 % of end-stage renal disease cases globally, with IgAN nephropathy and diabetic nephropathy representing >60 % of progressive CKD subtypes. Despite its clinical burden, no FDA-approved anti-fibrotic therapies exist to halt disease progression, underscoring a critical unmet need. Emerging evidence highlights Twist1, a basic helix-loop-helix (bHLH) transcription factor, as a pivotal driver of renal fibrosis by orchestrating epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) accumulation in tubular epithelial cells (TECs). In our experiment, Twist1 expression correlates strongly with fibrosis severity and inversely with estimated glomerular filtration rate (eGFR) in IgAN nephropathy and diabetic nephropathy biopsies. Here, we identify Harmine, a β-carboline alkaloid, as a first-in-class Twist1 inhibitor with therapeutic potential for renal fibrosis. In vitro, Harmine dose-dependently suppressed hypoxia-induced EMT in HK-2 cells, reducing vimentin expression and restoring E-cadherin at 5 μmol/L and 10 μmol/L. In murine models, Harmine (2.5, 5, 10 mg/kg/day) attenuated renal fibrosis in unilateral ischemia-reperfusion injury (uIRI) and unilateral ureteral obstruction (UUO) models. Safety profiling revealed an in vitro LD50 > 50 μM in HK-2 cells within 48 h, and no observable adverse effects in mice at therapeutic doses, with serum creatinine remaining stable throughout treatment. This study elucidates a novel mechanism for renal fibrosis inhibition through Twist1 suppression and positions Harmine as a promising candidate for preclinical development. By targeting a central node in fibrogenesis while maintaining systemic safety, Harmine addresses a critical gap in CKD therapy and warrants further investIgANtion in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Twist-Related Protein 1HarmineRenal Insufficiency, ChronicNuclear ProteinsKidneyAnimalsHumansFibrosisEpithelial-Mesenchymal TransitionMaleCell LineMiceMice, Inbred C57BLDisease Models, Animal

Stichwörter der Autor:innen

Chronic kidney diseaseHarmineIC50LD50Renal fibrosisTwist1

Substanzen

Twist-Related Protein 1HarmineNuclear ProteinsTWIST1 protein, humanTwist1 protein, mouse

Autor:innen und Institutionen

  • Department of Nephrology, Xijing Hospital, Air force Medical University, Xi'an, Shaanxi, China; Department of Nephrology, Xijing Hospital, Air force Medical University, Shaanxi Provincial Clinical Research Center for Ki…
  • Department of Nephrology, Xijing Hospital, Air force Medical University, Xi'an, Shaanxi, China.
  • Department of Geriatrics, Xijing Hospital, Air force Medical University, Xi'an, Shaanxi. China.
  • School of Medicine, Northwest University, 229 Taibai North Road, Xi'an, Shaanxi 710032, China. Electronic address: liulimin@nwu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, L., Gao, J., Xing, Y., Ning, X., Wei, L., He, P., Yang, Y., Bai, X., Liu, L., & Sun, S. (2026). Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115902

Vancouver

Huang L, Gao J, Xing Y, Ning X, Wei L, He P, et al. Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115902

BibTeX
@article{Huang2026,
  author = {Huang, Liuyifei and Gao, Jingli and Xing, Yan and Ning, Xiaoxuan and Wei, Lei and He, Peng and Yang, Yifan and Bai, Xiao and Liu, Limin and Sun, Shiren},
  title = {Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2025.115902}
}
Kostenlos starten →